Table 2. IHC and NGS parameters in the entire cohort and by tumor location (right colon, left colon, rectum).
| Parameters* | Entire cohort (n=412) | Right colon (n=139) | Left colon (n=171) | Rectum (n=102) | p-value | |
|---|---|---|---|---|---|---|
| IHC | ||||||
| MMR status | <0.001 | |||||
| Deficiency | 40 (11.1%) | 31 (25.8%) | 6 (4.0%) | 3 (3.3%) | ||
| Proficiency | 320 (88.9%) | 89 (74.2%) | 144 (96.0%) | 87 (96.7%) | ||
| Missing | 52 | |||||
| CD8+ density | <0.001 | |||||
| High^ | 118 (28.6%) | 57 (41.0%) | 32 (18.7%) | 29 (28.4%) | ||
| Other^ | 294 (71.4%) | 82 (59.0%) | 139 (81.3%) | 73 (71.6%) | ||
| NGS | ||||||
| BRAF | 0.020 | |||||
| No | 321 (92.5%) | 99 (86.8%) | 141 (95.3%) | 81 (95.3%) | ||
| Yes | 26 (7.5%) | 15 (13.2%) | 7 (4.7%) | 4 (4.7%) | ||
| TP53 | 0.013 | |||||
| No | 158 (45.5%) | 61 (53.5%) | 54 (36.5%) | 43 (50.6%) | ||
| Yes | 189 (54.5%) | 53 (46.5%) | 94 (63.5%) | 42 (49.4%) | ||
| FBXW7 | 0.002 | |||||
| No | 309 (89.0%) | 104 (91.2%) | 138 (93.2%) | 67 (78.8%) | ||
| Yes | 38 (11.0%) | 10 (8.8%) | 10 (6.8%) | 18 (21.2%) | ||
| PALB2 | 0.026 | |||||
| No | 321 (92.5%) | 107 (93.9%) | 141 (95.3%) | 73 (85.9%) | ||
| Yes | 26 (7.5%) | 7 (6.1%) | 7 (4.7%) | 12 (14.1%) | ||
| PIK3CA | 0.018 | |||||
| No | 284 (81.8%) | 84 (73.7%) | 129 (87.2%) | 71 (83.5%) | ||
| Yes | 63 (18.2%) | 30 (26.3%) | 19 (12.8%) | 14 (16.5%) | ||
*analysis was performed in informative samples.
Abbreviations: IHC: immunohistochemistry, IQR: interquartile range, MMR: mismatch repair, n: number, MUT: mutation, NGS: next-generation sequencing, N/A: not applicable, SD: standard deviation; ^: High: high CD8+ density, stromal AND intratumoral (in direct contact with cancer cells); Other: only stromal high OR only intratumoral high OR none high.